SCHEMBL2139382

SCHEMBL2139382

Cc1ccc(C(N)=O)c(NC(=O)c2csc(-c3cnccc3C(F)(F)F)n2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
IRAK4 Q9NWZ3 5/20 0.43
MAPK1 P28482 4/20 0.43
MAPT P10636 3/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 2/20 0.42
IDE P14735 1/20 0.42
MAPK10 P53779 1/20 0.42
PIM1 P11309 4/20 0.42
NPSR1 Q6W5P4 1/20 0.40
PIM3 Q86V86 2/20 0.40
PIM2 Q9P1W9 2/20 0.40
CD38 P28907 1/20 0.40
RAB9A P51151 3/20 0.39
ATM Q13315 2/20 0.39
NPC1 O15118 2/20 0.39
RAD52 P43351 1/20 0.39
SCN10A Q9Y5Y9 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2139885 0.83 IRAK4 (0.56) TDP1IRAK4MAPK1MAPTLMNA
SCHEMBL2139408 0.81 IRAK4 (0.67) IRAK4MAPK1RAB9AATMNPC1
SCHEMBL6786449 0.78 KDM4E (0.70) KDM4ETDP1IRAK4MAPK1MAPT
SCHEMBL2137407 0.76 SCN10A (0.44) IRAK4MAPK1MAPTLMNAPOLB
SCHEMBL10054633 0.76 TLR7 (0.47) TDP1IRAK4MAPK1LMNAPOLB
SCHEMBL1830298 0.75 RAB9A (0.44) TDP1IRAK4MAPK1MAPTLMNA
SCHEMBL2142275 0.75 RAB9A (0.46) TDP1IRAK4MAPK1LMNAPOLB
SCHEMBL2141469 0.75 RAB9A (0.46) TDP1IRAK4MAPK1LMNAPOLB
SCHEMBL4238040 0.75 CHEK1 (0.52) TDP1IRAK4MAPK1LMNAPOLB
SCHEMBL2140620 0.73 IRAK4 (0.67) IRAK4MAPK1MAPTRAB9AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2231652-B1 NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT Bayer Pharma AG (DE) 2012-05-30 EP claimed
US-8148411-B2 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-04-03 US claimed
US-20090203715-A1 NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS BAYER SCHERING PHARMA AG (DE) 2009-08-13 US claimed
EP-2070924-A1 New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine Bayer Schering Pharma Aktiengesellschaft (DE) 2009-06-17 EP claimed
EP-2231652-B1 NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT Bayer Pharma AG (DE) 2012-05-30 EP disclosed
EP-2231652-B1 NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT Bayer Pharma AG (DE) 2012-05-30 EP disclosed
US-8148411-B2 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-04-03 US disclosed
US-8148411-B2 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-04-03 US disclosed
US-8148411-B2 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-04-03 US disclosed
EP-2231652-A1 NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT Bayer Schering Pharma Aktiengesellschaft (DE) 2010-09-29 EP disclosed
US-20090203715-A1 NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS BAYER SCHERING PHARMA AG (DE) 2009-08-13 US disclosed
US-20090203715-A1 NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS BAYER SCHERING PHARMA AG (DE) 2009-08-13 US disclosed
US-20090203715-A1 NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS BAYER SCHERING PHARMA AG (DE) 2009-08-13 US disclosed
WO-2009074246-A1 NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-06-18 WO disclosed
WO-2009074246-A1 NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-06-18 WO disclosed
EP-2070924-A1 New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine Bayer Schering Pharma Aktiengesellschaft (DE) 2009-06-17 EP disclosed
EP-2070924-A1 New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine Bayer Schering Pharma Aktiengesellschaft (DE) 2009-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203715-A1 NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS CNR2, CYP11B2, CYP2C19 KDM4E 1799/4885TDP1 4292/4885IRAK4 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.